Roche and GSK in MEK/BRAF melanoma combo face off
This article was originally published in Scrip
Executive Summary
Roche/Genentech and GlaxoSmithKline have both presented new data on their MEK/BRAF inhibitor combination regimens in their battle for BRAF V600 mutation-positive melanoma market at ESMO. Overall the two companies' regimens are set to change the standard of care for this indication, and with the efficacy profiles looking too tight to call, it seems that the relative side effect profiles of the two regimens will determine their eventual success.